TAK-577

PreclinicalBiologic

Takeda

TAK-577 is one of 24 biologic programs targeting Von Willebrand disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Willebrand DiseaseActive, not recruiting

Von Willebrand DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Von Willebrand Disease

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Phase 3

3 2

Advate

Takeda

Phase 3

2 3

Bypassing Agents

Biostate

3 5

Hemlibra

Roche

Phase 1

1 6

Recombinant Factor IX

BBaxalta now part of Shire

Phase 3

1 7

Wilate

Octapharma

Phase 3

1 8

Rfviii

UUniversity of Pittsburgh

Phase 3

1 9

Vonicog Alfa

Takeda

Phase 3

3 10

Factor VIII Concentrates

Roche

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Von Willebrand disease1 trial

Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

Available· Takeda logo

Takeda··NCT06173024

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAK-577. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAK-577 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAK-577. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: Takeda

TAK-577

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Von Willebrand disease1 trial

References

Drug Info

Quick Facts

Related News